171 related articles for article (PubMed ID: 20845738)
1. [Immunity against influenza virus infection].
Takada A
Nihon Rinsho; 2010 Sep; 68(9):1625-30. PubMed ID: 20845738
[TBL] [Abstract][Full Text] [Related]
2. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
[TBL] [Abstract][Full Text] [Related]
3. Influenza vaccine immunology.
Dormitzer PR; Galli G; Castellino F; Golding H; Khurana S; Del Giudice G; Rappuoli R
Immunol Rev; 2011 Jan; 239(1):167-77. PubMed ID: 21198671
[TBL] [Abstract][Full Text] [Related]
4. Trends in development of the influenza vaccine with broader cross-protection.
Stropkovská A; Janulíková J; Varecková E
Acta Virol; 2010; 54(1):7-19. PubMed ID: 20201609
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.
Tamura S; Tanimoto T; Kurata T
Jpn J Infect Dis; 2005 Aug; 58(4):195-207. PubMed ID: 16116250
[TBL] [Abstract][Full Text] [Related]
6. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
[TBL] [Abstract][Full Text] [Related]
7. Age-related changes in magnitude and diversity of cross-reactive CD4+ T-cell responses to the novel pandemic H1N1 influenza hemagglutinin.
Subbramanian RA; Basha S; Brady RC; Hazenfeld S; Shata MT; Bernstein DI
Hum Immunol; 2010 Oct; 71(10):957-63. PubMed ID: 20650295
[TBL] [Abstract][Full Text] [Related]
8. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
[TBL] [Abstract][Full Text] [Related]
9. Pandemic preparedness: toward a universal influenza vaccine.
Roose K; Fiers W; Saelens X
Drug News Perspect; 2009 Mar; 22(2):80-92. PubMed ID: 19330167
[TBL] [Abstract][Full Text] [Related]
10. Keeping the memory of influenza viruses.
Combadière B; Sibéril S; Duffy D
Pathol Biol (Paris); 2010 Apr; 58(2):e79-86. PubMed ID: 20303671
[TBL] [Abstract][Full Text] [Related]
11. Heterosubtypic antibodies to influenza A virus have limited activity against cell-bound virus but are not impaired by strain-specific serum antibodies.
Wyrzucki A; Bianchi M; Kohler I; Steck M; Hangartner L
J Virol; 2015 Mar; 89(6):3136-44. PubMed ID: 25552718
[TBL] [Abstract][Full Text] [Related]
12. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
13. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
[TBL] [Abstract][Full Text] [Related]
14. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
[TBL] [Abstract][Full Text] [Related]
15. Defense mechanisms against influenza virus infection in the respiratory tract mucosa.
Tamura S; Kurata T
Jpn J Infect Dis; 2004 Dec; 57(6):236-47. PubMed ID: 15623947
[TBL] [Abstract][Full Text] [Related]
16. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
17. Toward a broadly protective influenza vaccine.
Doherty PC; Kelso A
J Clin Invest; 2008 Oct; 118(10):3273-5. PubMed ID: 18802488
[TBL] [Abstract][Full Text] [Related]
18. Recognition of influenza virus hemagglutinin by subtype-specific and cross-reactive proliferative T cells: contribution of HA1 and HA2 polypeptide chains.
Katz JM; Laver WG; White DO; Anders EM
J Immunol; 1985 Jan; 134(1):616-22. PubMed ID: 3871116
[TBL] [Abstract][Full Text] [Related]
19. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.
Bianchi E; Liang X; Ingallinella P; Finotto M; Chastain MA; Fan J; Fu TM; Song HC; Horton MS; Freed DC; Manger W; Wen E; Shi L; Ionescu R; Price C; Wenger M; Emini EA; Cortese R; Ciliberto G; Shiver JW; Pessi A
J Virol; 2005 Jun; 79(12):7380-8. PubMed ID: 15919893
[TBL] [Abstract][Full Text] [Related]
20. Seed viruses containing novel avian HA and NA antigens for prevention against potential influenza pandemic.
Li S; Perdue ML; Patzer E
Dev Biol (Basel); 2002; 110():135-41. PubMed ID: 12477316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
